Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The clinical syndrome of PSP responds poorly to all available forms of therapy used in Parkinson's Disease (PD). Currently, no effective treatment exists. Coenzyme Q10 in high doses has been shown to be a beneficial therapy in PD and might possibly be a beneficial therapy for PSP. This study will compare the efficacy, safety and tolerability of Coenzyme Q10 versus placebo in patients with atypical parkinsonian syndrome, progressive supranuclear palsy (PSP).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
30 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients fulfilling the diagnostic criteria of PSP/diagnosed within the past 5 years
Either vertical supranuclear palsy or both slowing of vertical saccades
Prominent postural instability with falls in the first year of disease onset
No evidence of other diseases that could explain the foregoing features
Current or previous therapeutic use of CoQ10
Parkinsonism due to drugs
History of pallidotomy, thalamotomy, active deep brain stimulator or fetal tissue transplant
History of active epilepsy, stroke, structural brain disease
Use of methylphenidate hydrochloride, cinnarizine, reserpine, amphetamines, or monoamine oxidase-A inhibitors within 3 months before the baseline visit.
Active cancer or cancer undergoing treatment
Participation in other drug studies or the use of other investigational drugs within 30 days before screening.